Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007991 · ClinicalTrials.gov registry record · Phase 2
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
A Phase 2 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT04007991 is a Phase 2 study that has completed, run by Emalex Biosciences. The registered enrollment target is 153 participants.
The verdict
NCT04007991, a Phase 2 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets
Interventions
- DRUG Placebo
- DRUG Ecopipam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2021-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04007991
The ClinicalTrials.gov registry entry for NCT04007991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04007991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04007991 about?
NCT04007991 is a clinical study titled "Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents". This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets
What is the current status of trial NCT04007991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2019-06-28. Estimated completion is 2021-09-23.
What interventions are being tested in trial NCT04007991?
The interventions under investigation include: Placebo (DRUG), Ecopipam (DRUG).
Who is sponsoring clinical trial NCT04007991?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.